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Abstract 
Although acquired mutations in KIT are commonly detected in various categories of 
mastocytosis, the methodologies applied to detect and quantify the mutant type and allele burden in 
cells and various tissues are poorly defined. We here propose a consensus on methodologies used to 
detect KIT mutations in patients with mastocytosis at diagnosis and during follow up with sufficient 
precision and sensitivity in daily practice. In addition, we provide recommendations for sampling 
and storage of diagnostic material as well as a robust diagnostic algorithm. Using highly-sensitive 
assays, KIT D816V can be detected in peripheral blood leukocytes from most patients with systemic 
mastocytosis (SM) which is a major step forward in screening and SM diagnosis. In addition, the KIT 
D816V allele burden can be followed quantitatively during the natural course or during therapy. Our 
recommendations should greatly facilitate diagnostic and follow up investigations in SM in daily 
practice as well as in clinical trials. In addition, the new tools and algorithms proposed should lead to 
a more effective screen, early diagnosis of SM, and help to avoid unnecessary referrals. 
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Introduction 
 Mast cells (MCs) and their committed progenitors express KIT,
1
 a transmembrane type III 
tyrosine kinase receptor also found in melanocytes, hematopoietic stem cells, germ cells and 
interstitial cells of Cajal.
2
 The ligand of KIT, stem cell factor (SCF), induces MC development from 
uncommitted and MC-committed hematopoietic precursor cells.
3
 In the human system, MC-
committed progenitors reside in the bone marrow (BM) and circulate in the peripheral blood (PB), 
whereas mature MCs usually are tissue-fixed non-circulating cells, found in virtually all vascularized 
organs.
4-6
 
 Mastocytosis is a rare and heterogeneous disease characterized by the accumulation of 
clonal MCs in one or multiple organs. The disease is mostly acquired, although rare familial cases 
have been described.
7
 Mastocytosis can affect both children and adults.
8
 In most pediatric patients, 
the disease affects only the skin, with different types of lesions.
9
 In these cases, the disease is termed 
cutaneous mastocytosis, CM. In CM the biopsy of lesional skin reveals MC infiltration, sometimes 
with atypical MCs forming aggregates in local areas.
10
 In children, the disease has a tendency to 
regress spontaneously,
11
 although some persist into adulthood.
12
 By contrast, in most adult patients, 
the disease is systemic and chronic and affects almost invariably the BM. These cases are called 
systemic mastocytosis (SM). In most patients, indolent SM (ISM) is diagnosed and the skin and BM 
are affected.
11
 More aggressive subtypes of SM are rare and include aggressive SM (ASM) and MC 
leukemia (MCL). Depending on data-source and center, 5 to 20% of all SM patients present with or 
develop an associated clonal hematological non-MC-lineage disease (SM-AHNMD).
13
 Symptoms in 
mastocytosis may occur from diverse effects of mediators that are released from neoplastic MCs, 
and, in case of ASM or MCL, from organ infiltration by MCs, with subsequent organomegaly and/or 
organ damage.
14
 
 Patients with mastocytosis are diagnosed and classified according to the proposal of the 
World Health Organization (WHO) which distinguishes 7 categories of mastocytosis: CM, ISM, SM-
©    2015 Macmillan Publishers Limited. All rights reserved.
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AHNMD, ASM, MCL, MC sarcoma (MCS) and extracutaneous mastocytoma.
15-17
. For some of 
these categories (CM, ISM, SM-AHNMD, ASM and MCL), subvariants have been identified, based 
on clinical and/or biological features.
15-17
 For patients with SM, the WHO has provided one major 
diagnostic criterion (infiltrates of >15 aggregated MCs identified through tryptase immuno-
histochemistry or other stains in sections obtained from BM and/or other extracutaneous organ(s)) 
and four minor SM diagnostic criteria based on i) the presence of atypical MCs in lesional tissues, ii) 
the presence of an activating point mutation in codon 816 in KIT in BM, PB, or any extracutaneous 
organ, iii) the expression of CD2 and or CD25 by neoplastic MCs and iv) a persistently elevated 
(>20 ng/mL) serum tryptase level .
18
 The diagnosis SM can be established when at least the major 
and one minor or three minor criteria are found.
18
 
 In adult patients, an activating KIT D816V mutation (c.2447A>T), located in the 
phosphotransferase domain (PTD) of the receptor is found in >80% of all cases. The exact 
percentages vary depending on disease subtypes (e.g., ISM vs. ASM) and cell source (e.g., BM vs. 
PB).
19-22
 By contrast, a KIT mutation is found in skin biopsy samples in nearly 75% of affected 
children but only one third present with KIT D816V.
23
 Other KIT mutations found in childhood 
mastocytosis are mainly located in the extracellular domain of the receptor (codon 8 or 9 of the KIT 
gene), the most frequently retrieved being a deletion at position 419 of the protein (codon 8; 
c.1255_1257delGAC).
23
 
In most SM patients, particularly in ISM, the number of neoplastic MCs in the BM is low 
(low MC burden).
24
 Thus, the relatively low sensitivity of conventional PCR in combination with 
sequencing of PCR products may result in false-negative cases. Indeed, in these patients, the median 
level of KIT D816V mutant alleles (also referred as to “KIT D816V allele burden”), is often below 
1%, as measured by recently developed allele-specific quantitative PCR assays (ASO-qPCR), that 
are based on either DNA or on RNA/cDNA, but have a similar (high) sensitivity.
21, 25, 26
 In addition, 
although rarely seen, SM patients may present with KIT mutations other than D816V, e.g., D816H, 
©    2015 Macmillan Publishers Limited. All rights reserved.
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D816Y, or even mutations outside the PTD of KIT.
27
 The latter can only be detected by PCR assays 
that are not routinely used, e.g., restriction fragment length polymorphism (RFLP) or high-
performance liquid chromatography (HPLC) of PCR products, but not by ASO-qPCR.
21, 28
  
Recent reports using ASO-qPCR (on DNA or RNA/cDNA) have shown correlations between 
KIT D816V allele burden and clinical parameters such as disease subtype, prognosis and survival.
21, 
26, 29
 Moreover, serial measurements of the KIT D816V allele burden by these ASO-qPCR techniques 
appear useful for monitoring of residual disease in aggressive subtypes during or after cytoreductive 
therapy or allogeneic stem cell transplantation.
21, 26
 
The present article provides consensus recommendations from members of the European 
Competence Network on Mastocytosis (ECNM
30, 31
) for standardized approaches and techniques to 
detect KIT mutations and to measure KIT mutant allele burden as part of the routine diagnostic work-
up, prognostication and follow-up during or after treatment in patients with mastocytosis. Consensus 
recommendations have been developed and discussed among co-authoring members of the ECNM 
between September 2013 and September 2014. Consensus statements were discussed until complete 
consensus (all experts agreed) was reached (or not reached by September 2014) and only those 
consensus statements where complete consensus was reached have been included as such in the 
current article. Other points of discussions are labeled as open issues (under discussion or still under 
development) in our consensus document.  
 
Short overview on the spectrum of KIT mutations and their clinical implications  
 KIT is encoded by a 21 exon-containing gene located on human chromosome 4q12 
(GenBank accession number: NG_007456).
32
 The resulting 976 amino acids-containing receptor has 
a molecular weight of 145 kDa.
33
 A schematic representation of wild type KIT (KIT WT) is shown 
in Figure 1. The receptor is composed of an extracellular domain (ECD), a transmembrane domain 
(TMD), a juxtamembrane domain (JMD) and a tyrosine kinase domain (TKD). The TKD contains an 
©    2015 Macmillan Publishers Limited. All rights reserved.
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ATP-binding site and a PTD (Figure 1). Several single nucleotide polymorphisms (SNPs) have been 
described in the KIT gene, such as for instance M541L (c.1621A>C), K546K (c.1638A>G), I798I 
(c.2394C>T), N828N (c.2484C>T) and L862L (c.2586C>G).
34
 The most common of these SNPs 
(percentage in the European population: 16.1%) is the ATG to CTG transition in codon 541 (exon 
10) giving rise to a M541L KIT protein sequence variation, which seems to confer increased 
sensitivity to the KIT ligand (SCF), although the clinical impact of this SNP remains unclear.
35
 
Activating mutations in KIT were first described in SM patients,
36
 and more recently in 
children with CM.
23
 In adult patients with ISM, ASM or SM-AHNMD, these mutations affect 
mainly the PTD of KIT, encoded by exon 17, usually at position 816 (most commonly KIT 
D816V),
37
 whereas in children, ECD mutants are also found.
23
 In MCL, the presence of the KIT 
D816V mutation seems less frequent than in other categories of SM.
38
 Finally, in the rare cases of 
familial mastocytosis, often presenting as pediatric CM, most cases exhibit no KIT mutations or 
uncommon germline mutations.
39-43
 However, even somatic KIT mutations have been described in 
familial mastocytosis.
23, 44, 45
 Figure 2 presents all currently known KIT mutations retrieved in the 
literature for adult and children mastocytosis patients, together with their approximate frequencies. 
 SM-AHNMD (5 to 20% of all SM cases) is a special subvariant of the disease.
13
 In most 
patients, an associated myeloid neoplasm is diagnosed, such as chronic myelomonocytic leukemia 
(CMML), atypical chronic myeloid leukemia (aCML), myelodyspastic/myeloproliferative neoplasm 
unclassifiable (MDS/MPN-u), MDS, chronic eosinophilic leukemia (CEL), AML or MPN-u.
13, 46-49
 
By contrast, lymphoid variants of AHNMD (multiple myeloma, B-cell lymphoma, chronic 
lymphocytic leukemia) are rarely found.
46, 50, 51
 Interestingly, a recent study of 48 SM-AHNMD 
patients has shown that the KIT D816V mutation can be detected in almost all these individuals 
except those with SM with an associated CEL.
52
 In most patients with SM-CMML, KIT D816V is 
detectable in AHNMD cells, suggesting the involvement of a common myelomono- and mastocytic 
precursor. In patients with SM-MPN and SM-AML, the KIT mutant D816V is also detectable, albeit 
©    2015 Macmillan Publishers Limited. All rights reserved.
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at a lower frequency.
53
 Finally, in patients with lymphoproliferative AHNMDs, the AHNMD cells 
are usually negative for KIT 816 mutation.
19, 52
 Table 1 shows the frequency and distribution of the 
different KIT mutations in the diverse subtypes of mastocytosis based on current knowledge and 
recently published data.
27
  
For each SM patient, the precise knowledge of the structure of KIT in neoplastic cells is of 
great clinical significance since the A-loop mutations D816V/H/Y/N induce resistance to imatinib in 
vitro as well as ex vivo in patients’ cells,54, 55 This resistance has been attributed to the fact that the 
KIT D816V mutant disrupts the structure of the receptor, leading permanently to an active 
conformation, which cannot be targeted by imatinib.
56, 57
 This resistance of the most frequently 
identified KIT mutant in SM against imatinib has led to the use of non-targeted cytoreductive 
therapy, such as cladribine (2CdA),
58
 or interferon- ,
59
 and to clinical trials with novel tyrosine 
kinase inhibitors (TKIs) that overcome resistance in these patients, such as PKC412 (midostaurin) 
with encouraging results.
60, 61
 By contrast, the rare SM patients presenting with a KIT mutant outside 
the PTD (e.g. JMD or ECD mutants), or with no KIT mutation may respond to imatinib.
39, 41, 62, 63
 
 
Recommendations for cells and assays to be used for KIT mutation analysis 
 This section will first describe the differences in the management between pediatric and 
adult patients. We will then highlight the various samples and cell types to be used for detection of 
KIT mutations in different subtypes of mastocytosis, as well as the different techniques used for this 
purpose, their advantages and possible limitations. Finally, we will provide recommendations for the 
most appropriate procedures to be applied at time of diagnosis and during follow-up. 
 
Pediatric mastocytosis 
In childhood patients with CM, BM investigations are usually not required unless clinical 
findings and symptoms suggest the presence of a relevant (aggressive) systemic disease.
12
 In the 
©    2015 Macmillan Publishers Limited. All rights reserved.
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latter case, a thorough BM examination is recommended, including KIT mutation analysis.
18
 In some 
patients in whom the diagnosis CM is in question because of atypical skin lesions and/or a 
questionable histology, lesional skin can be examined for the presence of KIT mutations.
23
 However 
this test is not regarded as standard in typical CM, which may change in the future, especially if it 
appears that the presence of a particular mutation is associated with a certain prognosis or with 
disease persistence into adulthood. In some of these cases, sequencing of the entire KIT coding 
region may be required and should be performed according to standard methodologies.
23
 
 
Adult patients 
In SM, neoplastic MCs usually reside in the BM but are not found in the PB.
1
 Therefore, it 
has been standard to examine BM cells for the presence of KIT D816V.
64
 Until recently, the most 
frequently used assay for the detection of KIT mutations has been conventional sequencing of PCR-
derived amplicons. However, the level of sensitivity of this technique is rather low (10-20%) which 
may lead to false-negative results, especially when the degree of BM infiltration is low.
65
 
Consequently, considerable efforts have recently been made to improve assay sensitivities using 
different approaches, including PCR amplification followed by restriction digestion (PCR+RFLP),
24
 
peptide nucleic acid (PNA)-mediated PCR clamping,
66
 nested RT-PCR followed by denaturing high-
performance liquid chromatography (DHPLC),
21
 and ASO-qPCR assays.
21, 22, 67, 68
 More 
sophisticated techniques, including enrichment of MCs and other cell types from BM samples via 
laser micro-dissection or fluorescence-activated cell sorting (FACS) followed by PNA-mediated 
PCR-clamping technique, are used for research purposes but are not routinely used for diagnostic 
algorithms in most centers.
29, 66, 69-71
 
 
Recommended tissues and cells for KIT mutation analysis 
©    2015 Macmillan Publishers Limited. All rights reserved.
10 
 
While it is generally recommended that fresh samples should be used whenever possible, 
storage of cells and isolation of total RNA or DNA from stored cells is also acceptable, provided that 
standard-methods are applied: cell suspensions should be stored in liquid nitrogen, extracted RNA 
should be stored at −70°C (or as cDNA at or below -20°C) and DNA at or below -20°C. 
In suspected SM, the diagnostic standard is to examine unfractionated BM cells (after 
erythrocyte-lysis) or mononuclear marrow cells (MNC) for KIT mutations.
18
 The BM aspirate (1-2 
mL) should be recovered in EDTA or in stabilizator-free heparin. In certain circumstances, when no 
BM aspirate sample is available, KIT mutational analyses can be performed on cells detached from 
BM smears or from a paraffin-embedded biopsy sample, provided that the procedure used to 
determine the KIT mutational status exhibits sufficient sensitivity.
72
 A practical issue here is that if 
BM aspirate is not obtainable, the core biopsy preservative should be formalin, and not Zencker’s or 
Bouin’s which degrades DNA. 
In typical ISM, MNCs from PB are frequently KIT D816V negative when investigated by low 
sensitivity techniques, such as sequencing of PCR-derived amplicons. However, recent studies using 
ASO-qPCR-assays have suggested the possibility of detecting the mutation in PB in nearly all adult 
patients with typical SM.
21, 22, 26
 Thus, we recommend the use of ASO-qPCR-assays on DNA or 
RNA/cDNA derived from PB samples as a screening test in cases with suspected SM.
64
 However, 
the KIT D816V mutation may not be detected in all patients with SM by this approach, especially in 
the few cases where other mutations in KIT are present or the MC burden is extremely low. 
Therefore, we recommend testing of PB cells for initial screening, whereas a more detailed analysis 
must always include a thorough examination of the BM by a sensitive technology, such as the 
currently most widely used ASO-qPCR,
21, 22
 or following MCs purification, by laser microdissection 
or flow cytometry.
19, 69
 However, most centers have focused on developing sensitive ASO-qPCR 
assays rather than methods to purify MCs. Of note, strict precautions should be undertaken to 
prevent false-positive results.
73
  
©    2015 Macmillan Publishers Limited. All rights reserved.
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Regarding adult patients with skin lesions (also referred as to “mastocytosis in the skin”, 
MIS), a skin biopsy can be performed, where the presence of KIT D816V is thus indicative for 
MIS.
11
 Nonetheless, this result is not diagnostic for SM which still requires the demonstration of the 
presence of KIT D816V in the BM or PB.
64
 In addition, other visceral organs, such as the spleen, 
liver, gastro-intestinal (GI) tract or lymph nodes, may be affected in SM.
74-81
 However, we do not 
recommend routine screening of these organs for the presence of KIT mutations. Involvement of a 
single extramedullary (visceral) organ in SM in the absence of BM involvement is an extremely rare 
condition.
82, 83
 In such exceptional cases, it has been demonstrated that KIT mutations may also be 
detected in the involved organs.
81, 84
 
 
Standard assays for detection of KIT D816V 
Several assays for detection of the KIT D816V mutation have been developed and reported. 
Based on literature-data, the most sensitive assays, briefly described below, are i) RT-PCR plus 
RFLP, ii) nested RT-PCR followed by D-HPLC of PCR amplicons, iii) PNA-mediated PCR, and iv) 
ASO-qPCR on DNA or RNA/cDNA. These techniques should be regarded as standard, provided that 
they have sufficient specificity, sensitivity and precision. We thus recommend performing these 
techniques according to published protocols.
19, 21-23, 25, 66, 68, 72, 85
 The advantages, disadvantages and 
sensitivity of the different tests recommended are summarized in Table 2. 
 
RT-PCR and RFLP  
The sensitivity of this technique allows the detection of one KIT D816V+ cell among 2000 
KIT WT cells (0.05%).
18
 However, the technique has limitations since it does not allow the detection 
of other mutations in codon 816, and it is not quantitative.
18
 
 
Nested RT-PCR followed by D-HPLC of PCR amplicons  
©    2015 Macmillan Publishers Limited. All rights reserved.
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The major interest of this technique is that it allows detection of all mutations in the amplified 
region and would be perfect for simultaneous detection of KIT D816V or of other mutations in codon 
816 in the same reaction.
21
 The technique has been optimized to detect mutant KIT D816V down to 
0.5–1 % of mutant in normal cells based on cell line and RNA dilutions.21 
 
Peptide nucleic acid-mediated (PNA)-mediated PCR 
Three interesting features of this technique are that i) it allows detection of the mutated KIT 
D816V allele in a 1000-fold excess of WT background,
66
 ii) it allows the identification of other 
mutations in codon 816 or in adjacent codons,
72
 iii) it is the recommended method to be applied on 
formalin-fixed paraffin-embedded BM trephine biopsies.
19, 66, 72
  
 
Allele specific PCR (ASO-PCR) and ASO-quantitative PCR (ASO-qPCR)  
 ASO-PCR is a simple, fast and reliable method to detect specifically KIT D816V 
mutant in various tissues.
67
 Interestingly, the quantitative variant of the method (ASO-qPCR) has the 
advantage to allow simultaneously detection and allele burden measurement of KIT D816V in 
different tissues and cells (PB, BM and organ biopsies) at low cost (reagents <US $50).
22, 25, 68
 As an 
example, Kristensen et al. presented recently an assay that detects less than 0.01% KIT D816V 
mutation-positive cells.
68
 In their study, the authors analyzed a total of 61 samples derived from 31 
cases diagnosed with various SM subtypes and were able to detect the mutation in 95% of BM and 
81% of PB samples, respectively.
68
 The Danish group further confirmed the sensitivity and reliability 
of their assay on lesional skin biopsies with positive results in all out of 29 adult SM patients.
86
 In 
another study conducted on 25 ISM patients, the same authors showed that the method detects the 
KIT mutant in circulating PB cells even if no circulating MCs are detectable.
25
 From these data, the 
group proposed adopting mutation analysis of PB as a “routine” diagnostic screen test in 
mastocytosis.
22
 The sensitivity and specificity of the ASO-qPCR analysis of PB cells was also 
©    2015 Macmillan Publishers Limited. All rights reserved.
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examined. For this purpose, the authors analyzed PB samples in a total of 83 SM patients and 4 CM 
patients as well as 10 patients with a provisional diagnosis of MIS.
22
 In this study, KIT D816V was 
detected in 94% of all cases with SM. Interestingly, all 10 patients with MIS tested positive in this 
study, demonstrating the high sensitivity of the test in suspected SM.
22
 Based on this study and 
similar data from other centers,
21, 26
 the ECNM suggests that PB should be used for the initial 
screening of KIT mutations in suspected SM patients in daily practice.
64
 However, as already 
mentioned, an issue is that in case of very low numbers of clonal MCs, the KIT D816V mutation may 
not be detectable in PB. Therefore, BM cells need to be investigated in all cases with high suspicion 
of SM. However, concerning the ASO-qPCR, multi-center standardization projects (ring trials) 
aimed at inter-center validation as well as harmonization will be required in the future. Finally, a few 
issues remain to be solved for the future. Indeed, neither of the ASO-qPCR assays can detect other 
mutations at codon 816 of KIT (such as D816Y or D816H) or at positions outside the kinase 
domain.
21, 68
  
 
Usefulness of allelic burden measurements of KIT D816V in PB and BM  
 Very recent reports have shown that allele burden measurement of KIT D816V in BM and PB 
using sensitive ASO-qPCR on DNA or on RNA/cDNA are not only useful for diagnostic purposes 
but also for prognostication, follow-up of the disease as well as for quantification of response to 
treatment such as chemotherapy or allogeneic SCT.
21, 26
 
Indeed, Hoermann and colleagues quantified the KIT D816V allele burden from genomic 
DNA derived from BM aspirates and PB by ASO-qPCR in a cohort of 105 patients with 
mastocytosis, including cases with CM (n=12), MIS (n=3), ISM (n=67), SSM (n=5), ASM (n=7), 
SM-AHNMD (n=10) and MCL (n=1).
26
 Interestingly, the authors reported significant differences in 
the median allele burden between disease subgroups, with an increased burden found in advanced 
disease: CM (0.04%), ISM (0.3%), SSM (6.0%), ASM (9.3%), and SM-AHNMD (3.8%). 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Confirming previous data,
87
 the authors also reported a good correlation between the KIT D816V 
allele burden and the serum tryptase levels, whereas no significant correlation was found between the 
allele burden and the MC infiltration in the BM, which may be explained by the fact that non-MC-
lineage cells in the BM also harbor KIT D816V, but at levels that may greatly vary from patient to 
patient.
26
 Moreover, the authors were able to demonstrate that the KIT D816V allele burden was of 
prognostic significance. In fact, patients with ISM showed a stable allele burden during the follow-
up, whereas in case of progression, a marked increase in KIT D816V was found.
26
 Finally, the 
authors were able to show that the KIT D816V allele burden decreases during cytoreductive 
therapy.
26
  
In a similar study, Erben and colleagues used a KIT D816V ASO-qPCR on RNA/cDNA to 
diagnose mastocytosis and to monitor the allele burden as marker of residual disease.
21
 The SM 
patients analyzed (n=147) were classified as follows: ISM (n=63), SSM (n=8), SM-AHNMD (n=16) 
and ASM/MCL±AHNMD, (n=60). In 62 patients, samples were collected from BM and PB (ISM, 
n=28; SSM, n=4; SM-AHNMD, n=5; ASM/MCL, n=25). Thus, overall, 210 samples were 
analyzed.
21
 The authors observed that when compared to nested RT-PCR followed by HPLC and 
sequencing, their ASO-qPCR was more sensitive, detecting 0.01-0.1% of mutated cells. Independent 
of disease subtype, they identified the KIT D816V mutation in 97% of BM samples and in 78% of all 
PB samples tested.
21
 In addition, they showed a strong correlation between the KIT D816V allele 
burden, disease subtype (e.g., indolent vs. advanced SM) and survival.
21
 In terms of monitoring 
residual disease, respective analyses were performed on 4 ASM/MCL±AHNMD patients treated 
either with cladribine (n=1), aggressive chemotherapy (n=1) or allogeneic SCT (n=2). The authors 
reported a significant reduction of the KIT D816V allele burden in the BM and PB during 
treatment.
21
 
Thus, it appears that ASO-qPCR assays on DNA or on RNA/cDNA are highly sensitive 
methods for the quantification of the KIT D816V burden, and possibly preferable to nested PCR plus 
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RFLP or D-HPLC. Consequently, the ECNM recommends the use of the KIT D816V ASO-qPCR 
assays for the analysis of patients with suspected SM in PB and BM samples in routine screening 
tests.
18
 In KIT D816V-negative patients with an otherwise clear histologic and biochemical (tryptase) 
diagnosis of SM, PCR plus RFLP or D-HPLC can be used for the identification of an alternative 
mutation within exon 17. If also negative, sequencing of the complete coding region of KIT is 
recommended, preferably by the use of Next Generation Sequencing (NGS). 
 
Guidelines to search for and monitor KIT D816V+ SM  
RT-PCR+RFLP or D-HPLC, PNA-mediated PCR, and ASO-qPCR are fast, reliable, 
sensitive, and cost-effective methods for routine screening of KIT D816V in all SM subtypes. When 
applied on BM cells, all these assays have demonstrated their ability to detect the KIT D816V 
mutation in > 80% of SM patients, a sensitivity considered sufficient in daily practice.
18
 In addition, 
it has emerged that PB is sufficient for mutation analysis in many patients when the most sensitive 
assays are applied.
21, 26, 64
 Thus, we propose to use KIT D816V ASO-qPCR assays in PB in 
combination with measurement of serum tryptase and other relevant parameters, such as specific 
clinical symptoms indicating potential organ involvement, for the routine screening of adult patients 
with suspected mastocytosis, and these recommendations are summarized in a diagnostic algorithm 
for adult patients with suspected mastocytosis (Figure 3). In addition, Table 3 describes the 
usefulness of KIT D816V ASO-qPCR assays, together with several other clinical, biological, 
molecular and radiographic explorations, in the diagnosis and monitoring of the disease. However, 
the applied methodology should be validated carefully with respect to the expected diagnostic yield 
which can be reduced dramatically by even minor reductions in sensitivity.
22
 Thus, KIT mutational 
analysis in BM samples may be always performed following a positive test on PB samples, and 
should be considered in cases with high suspicion of SM even when no KIT mutation is detectable in 
©    2015 Macmillan Publishers Limited. All rights reserved.
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the PB. In addition, the frequency of measurement of the allele burden should be adapted to the 
individual situation in each patient. Thus, in ISM patients with low MC burden and stable clinical 
course, the KIT D816V allele burden should be measured at diagnosis, but should not necessarily be 
repeated, unless signs of disease progression occur. In patients with more aggressive forms and those 
enrolled in clinical trials with cytoreductive therapies, the KIT D816V allele burden should be 
measured repeatedly before and during therapy.  
 
Recommendations for SM cases with a “negative” KIT D816V test result 
In a small percentage of cases (<5-10%) no mutation is detectable in codon 816 of KIT,
19, 20
 
which may have several explanations: i) patients are in fact KIT D816V+ but the (very) low MC 
burden leads to a false negative result because the sensitivity of the applied assay is too low, ii) 
patients indeed only bear wild type KIT or iii) patients are positive for other mutations at codon 816 
(D816H, D816Y, others) or in other regions of KIT which are not detectable by the ASO-qPCR 
assays for KIT D816V. In scenario i) a KIT mutation may only be detected in highly enriched (sorted 
or microdissected) MCs or by using one of the highly sensitive techniques presented above.
19, 21, 26, 66, 
68
 However, enrichment is usually not required for decision-making in daily clinical practice as 
demonstration or exclusion of KIT D816V has no therapeutic consequence.  
By contrast, in patients with ASM or MCL (huge MC-infiltrates), a negative screen-result is a 
diagnostic challenge. In such cases, certain KIT mutations in the JMD, TMD or ECD domains or 
even KIT wild type may be excellent candidates for targeted treatment with imatinib.
54, 62, 63, 88-90
 
Therefore, a negative result should be confirmed, preferably in a reference laboratory, by using the 
most sensitive technique available today, i.e. ASO-qPCR. This is then followed by examination of 
KIT for other mutations in codon 816, which requires amplification of the codon 17 and sequencing 
of the resulting amplicons or preferably PNA-mediated PCR.
19
 Finally, if no mutation is found at 
codon 816, sequencing of the whole KIT coding sequences by NGS should be considered.
23
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Concluding remarks and future perspectives  
Highly sensitive and specific PCR-based assays for the detection of KIT D816V are now 
available. These methods have become standard in the routine screening of patients with suspected 
SM. Furthermore, quantification of the KIT allele burden may be rapidly adopted as gold standard 
for assessing the disease burden in advanced SM, thereby improving prognostication and monitoring 
of the disease course prior, during and after cytoreductive therapies, including KIT-targeting drugs 
and allogeneic SCT. However, although more than 80% of all SM patients harbor KIT D816V, SM is 
a heterogeneous disease regarding mutational patterns, course and aggressiveness. It has also been 
shown that additional genetic lesions such as mutations in TET2, SRSF2, ASXL1, SRSF2 or RUNX1 
are frequently identified in patients with advanced SM, preferably in ASM or MCL with AHNMD.
27, 
91, 92
 These lesions might decisively contribute to the clinical heterogeneity and the aggressiveness of 
SM and may represent new therapeutic targets. Thus, methods such as myeloid gene mutation 
panels, e.g. 20-50 genes being evaluated in parallel, or NGS, applied on the whole genome, will 
allow the mapping of additional functionally important molecular lesions, which may complement or 
even replace present techniques used for KIT mutation analyses as basis to improve our knowledge 
about the clinical course of patients with mastocytosis. 
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Figure Legends 
 
Figure 1: Structure of normal KIT (KIT Wild Type). The KIT gene, located on chromosome 
4q12 in humans, contains 21 exons transcribed/translated into a transmembrane receptor tyrosine 
kinase (RTK) of 145 kDa and 976 amino acids. KIT structure is characterized by 5 Ig-like subunits 
in the extracellular domain (ECD) which contains a ligand binding site (SCF for KIT) and a 
dimerization site, and is linked to a cytoplasmic region by a single transmembrane helix. The 
cytoplasmic region of KIT consists of an autoinhibitory juxta-membrane domain (JMD) and a kinase 
domain (KD) arranged in a proximal (N-) and a distal (C-) lobe linked by a hinge region. The C-lobe 
of RTKs type III includes a large Kinase Insert Domain (KID) of ~ 60-100 residues. The red star 
represents the position 816 where an Asp to Val point mutation (KIT D816V) is found in > 80% of 
adult systemic mastocytosis patients. The receptor is presented under its monomeric form, whereas a 
dimer results from stem cell factor (SCF) ligation. ECD: Extracellular domain; JMD: 
Juxtamembrane domain; KID: Kinase insert domain; PTD: phosphotransférase domain; TK: tyrosine 
kinase; TMD: transmembrane domain. 
 
Figure 2: Representation of the structure of KIT, illustrating the localization of the more 
frequently observed mutations in the KIT sequence in pediatric and adult patients with 
mastocytosis. The receptor is presented under its monomeric form, whereas its wild type counterpart 
dimerizes upon ligation with SCF before being activated in normal cells. In children, the KIT D816V 
PTD mutant (in red) is found in nearly 30% of the patients, whereas the ECD mutants (in blue) are 
found in nearly 40% of the affected children, the most frequent being the deletion 419. In adults, 
depending of the category of mastocytosis, the KIT D81V mutant (in red) is found in at least 80% of 
all patients. The complete list of KIT mutants retrieved in the literature for mastocytosis is depicted 
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here. In children, the structure of KIT is found WT in around 25% of the patients analyzed, whereas 
in adults, KIT is found WT in less than 20% of all patients analyzed so far. Some of the mutations 
are found only in a very few number of patients. Del: deletion; ECD: Extracellular domain; Ins: 
Insertion; ITD: Internal tandem duplication; JMD: Juxtamembrane domain; KI: Kinase insert; PTD: 
phosphotransferase domain; TMD: Transmembrane domain. ±: mutation found in less than 1% of the 
pediatric or adult patients; +: mutations found in 1 to 5% of pediatric patients; ++: mutation found in 
5 to 20% of pediatric patients; +++: mutation found in around 30% of pediatric patients and in > 
80% of all adult patients.*Mutation also found in children at low frequency. 
 
Figure 3: Proposed algorithm for the use of KIT D816V allele-specific quantitative PCR or RT-
PCR (ASO-qPCR) in peripheral blood (PB), together with serum tryptase measurement, for 
the screening of adult patients with suspected mastocytosis. In case of suspected mastocytosis in 
an adult patient, the first step is the search for clear signs of mastocytosis in the skin (MIS). If MIS is 
present, we recommend that a BM examination should be performed directly. If there is no MIS, we 
recommend to measure serum tryptase level, together with a KIT D816V ASO-qPCR using PB cells. 
If the serum tryptase level is > 15 ng/mL and/or the KIT D816V ASO-qPCR detects the mutation, a 
bone marrow examination is recommended, including a KIT D816V ASO-qPCR. If the BM studies 
are compatible with the diagnosis SM, and the KIT D816V ASO-qPCR is positive, then the final 
diagnosis is KIT D816V+ SM. If the BM studies are compatible with the diagnosis SM, and the KIT 
D816V ASO-q(RT)PCR is negative, sequencing of the entire KIT gene should be considered on a 
BM sample, in order to determine the KIT structure in this D816V-negative patient. In MIS-negative 
patients who have a serum tryptase level < 15 ng/mL and who are negative for the search of the KIT 
D816V mutant by ASO-qPCR on PB, we recommend to follow up the patients and to perform a BM 
investigation only if there is an increase in tryptase or clinical symptoms/signs suggesting the 
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presence of mastocytosis. Otherwise, alternative explanations and differential diagnoses should be 
considered. ASO-qPCR: allele specific-quantitative PCR on RNA or DNA; BM: bone marrow; CM: 
cutaneous mastocytosis; MIS: “mastocytosis in the skin”; PB: peripheral blood; SM: systemic 
mastocytosis; sTryptase: serum total tryptase level. 
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Table 1  
 
Major characteristics of the various categories of mastocytosis, and distribution of KIT 
mutations along these categories. 
 
Categories of disease and their 
major characteristics 
Relative 
frequency 
Prognosis Type and frequency of KIT 
mutations/presence of 
additional genetic lesions 
Pediatric mastocytosis  
 Disease frequently limited to the 
skin 
 Resolves at adolescence in most 
cases 
++  Usually 
very good  
 25% KIT WT23 
 35% KIT D816V (D816I or 
D816Y)
23
 
 40% ECD KIT mutations23 
Indolent Systemic Mastocytosis 
(ISM) 
 Mostly chronic and stable evolution 
over decades 
 Symptoms are mostly related to 
mediators released by MCs 
 Progression into a more aggressive 
disease is very rare 
++ Very good 
to good 
 > 80 % KIT D816V27 
 A few patients are KIT WT or 
may present non codon 816 
KIT mutations
19, 27, 37
 
 The presence of the KIT 
D816V mutation in non-MC 
lineages appears to be a 
predictor for risk of 
progression
29, 71
 
Smoldering Systemic Mastocytosis 
 Stable evolution over years or 
decades 
 Presence of a high MC burden in 
the BM 
 Presence of borderline begin 
symptoms (B-findings)* 
 Some patients may progress to 
more aggressive disease  
+ Relatively 
good 
 > 80 % KIT D816V11 
 Additional genetic non-KIT 
lesions may be acquired during 
the evolution if the patient 
progresses to a more 
aggressive disease
27
 
 
Aggressive Systemic Mastocytosis 
(ASM) 
 Presence of clinical signs related to 
organ dysfunction linked to MC 
infiltration (C-findings)** 
 Can transform into MCL 
+/- Poor  > 70% KIT D816V11 
 A few patients may present 
non codon 816 KIT 
mutations
11
 
 Additional genetic non-KIT 
lesions can be found 
27
 
Systemic mastocytosis with an 
Associated Hematological non MC 
disease (SM-AHNMD) 
 SM part can be indolent or 
aggressive 
 AHNMD component is mostly a 
myeloid neoplasm 
+ Depending 
on the type 
of SM and 
on the 
prognosis of 
the 
AHNMD 
 > 80% KIT D816V11 
 The AHNMD may present its 
own recurrent genetic lesion 
(BCR/ABL, JAK2 
V617F,…)93,13 
 Additional genetic non-KIT 
lesions can be found (see
27
) 
Mast Cell Leukemia (MCL) 
 >20% of atypical MCs in the BM 
smears 
 Presence of C-findings 
+/- Very poor  KIT D816V mutant is less 
frequent than in ISM
38
 
 KIT mutations in ECD or JMD 
or no KIT mutations are 
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frequent
38, 90, 94
 
 
Mast Cell Sarcoma (MCS) 
 Presence of very atypical malignant 
MCs in a solitary mass 
 Progress to MCL in a short time 
period 
+/-- Very poor  No KIT D816V mutation 
described to date 
 Other non codon 816 KIT 
mutations can be found
95-97
 
Familial mastocytosis  
 Reported in more than 50 families 
since the mid-1880s.  
 Mostly indolent pediatric CM 
 
+/- Usually 
very good 
 Rare somatic KIT D816V 
mutations described in a few 
adult-onset SM.
23, 44, 45
 
 Most cases without KIT 
mutations or with uncommon 
germline mutations (i.e., 
K509I, A533D, R634W, 
N822I, M835K, S849I or 
deletion of amino acids 419 or 
559-560).
39-43
 
 
*B-findings: hypercellular BM, dysplasia, organomegaly without organ failure, and high 
serum tryptase levels. 
**C-findings: organ dysfunction, such as cytopenia (ANC<1×10
9
/L, Hb<10 g/dL, or 
platelets<100×10
9
/l), hepatomegaly with impaired liver function, palpable splenomegaly with 
signs of hypersplenism, malabsorption with significant hypoalbuminemia, significant weight 
loss >10% over the last 6months and/or large osteolyses. 
AHNMD: associated clonal hematologic non-mast cell lineage diseases; ANC: absolute 
neutrophil count; ASM: aggressive systemic mastocytosis; BM: bone marrow; CM: cutaneous 
mastocytosis; ECD: extracellular domain; ISM: indolent systemic mastocytosis; MCL: mast 
cell leukemia; MCS: mast cell sarcoma; MCs: mast cells; WT: wild type. 
++: frequent; +: relatively frequent; +/-: rare; +/-- extremely rare. 
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Table 2: 
 
Summarized advantages, disadvantages and sensitivity of the different tests 
recommended to detect KIT mutations at position 816. 
 
Technique RT-PCR plus 
restriction 
fragment 
length 
polymorphism 
(RFLP) 
Nested RT-
PCR 
followed by 
D-HPLC of 
PCR 
amplicons 
PNA-
mediated 
PCR 
ASO-qPCR on DNA or 
RNA/cDNA 
Advantages -simple 
-fast 
-reliable 
-cost-saving 
-detects 
different 
KIT 
mutations at 
position 816 
 
-allows 
detection of 
KIT 
mutations at 
position 816 
or at adjacent 
positions 
-
recommended 
for formalin-
fixed 
paraffin-
embedded 
tissues 
-simple 
-fast 
-cost-saving 
-highly sensitive test 
-quantitative: allows the 
quantification of the KIT 
D816V allele burden in 
blood or BM at diagnosis 
or in the follow up 
 
Disadvantages -detects only 
KIT D816V 
mutant 
-not 
quantitative 
-relatively 
low 
sensitivity 
-not 
quantitative 
-time-
consuming 
-needs 
special 
facilities 
(HPLC) 
-not 
quantitative 
-intermediate 
 sensitivity 
-detects only KIT D816V 
mutant 
-needs 
standardization,validation 
and harmonization 
Sensitivity ± 0.05 % 0.5-1.0 % ± 0.1% ± 0.01% 
 
ASO-qPCR: allele specific-quantitative PCR; BM: bone marrow; D-HPLC: denaturing high-
performance liquid chromatography; PNA-mediated PCR: peptide nucleic acid-mediated; 
PCR RT-PCR: reverse transcriptase-polymerase chain reaction. 
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 Table 3:   
 
Recommended use of major clinical, biological and molecular parameters/explorations 
for the diagnosis and the follow up of adult patients with SM. 
 
Parameters/explorations Diagnosis Follow up in 
patients 
with stable 
SM 
Follow up in 
case of 
(suspected) 
progression in 
SM 
Follow up in 
during 
cytoreductive/ 
targeted 
therapy 
Clinical parameters 
 
- Careful dermatological 
examination (including Darier’s 
sign) 
 
- Palpation for hepatomegaly, 
splenomegaly and/or 
lymphadenopathy 
 
- Neuropshycological evaluation 
 
 
 
+ 
 
 
 
+ 
 
 
 
+ 
 
 
+ 
a
 
 
 
 
+ 
c
 
 
 
 
+ 
c
 
 
 
 
+ 
a
 
 
 
 
+ 
 
 
 
+ 
 
 
+ 
b
  
 
 
 
+ 
b
 
 
 
 
+ 
Biological parameters 
 
- Serum tryptase level 
- CBC and differential 
- BM biopsy with KIT (CD117) 
and tryptase staining by IHC 
- Cytological examination of BM 
smears 
- CD2/CD25 on BM MCs by IHC 
or flow cytometry 
- CD30 on BM MCs by IHC or 
flow cytometry 
- Serum LDH 
- Serum albumin 
- Serum calcium 
- Total IgE 
- Serum alkaline phosphatase 
- Liver function tests 
- Serum 2-microglobulin 
- Urinary histamine metabolites 
- Urinary PGD2 
 
 
+ 
+ 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
 
+ 
c
 
+ 
c 
- 
 
- 
 
- 
 
-
 
 
+ 
c
 
+ 
c
 
+ 
c
 
 
+ 
c
 
+ 
c
 
+ 
c
 
- 
- 
 
 
 
+ 
+ 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
- 
- 
 
 
+ 
d
 
+ 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
- 
- 
Molecular parameters 
 
-ASO-qPCR for KIT D816V 
mutation in PB 
-ASO-qPCR for KIT D816V 
mutation in BM 
- KIT sequencing 
- Testing for additional genetic 
lesions (NSG, myeloid gene 
 
 
+ 
 
+ (see Figure 3) 
 
+ (see Figure 3) 
+ (if ASM/MCL 
or SM-AHNMD) 
 
 
+ 
c 
 
- 
 
- 
-
 
 
 
+ 
 
+ 
 
- 
+ 
 
 
+ 
d
 
 
+ 
d
 
 
- 
+  
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panels) 
 
Radiographic explorations 
 
- Computed tomography  
- Ultrasonography 
- Osteodensitometry (T Score by 
Dexa-Scan) 
 
+ 
 
+ 
+ 
+ 
 
- 
 
- 
- 
+ 
+ 
 
+ 
+ 
+ 
 
+ 
 
+ 
+ 
+ 
 
 
ASM: aggressive systemic mastocytosis; ASO-qPCR: allele specific-quantitative PCR; BM: 
bone marrow; CBC: complete blood count, IHC: immunohistochemistry; MCL: mast cell 
leukemia; MCs: mast cells; MRD: minimum residual disease; NSG: nest generation 
sequencing; PGD2: prostaglandin D2; SM: systemic mastocytosis; SM-AHNMD: systemic 
mastocytosis with associated hematological non MC disease. 
a
 If skin lesions are evolutive 
b
 Lesions may regress upon treatment 
c
 At regular intervals, depending on the overall situation in each case 
d Useful to appreciate the efficacy of the treatment and to evaluate the level of MRD 
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